Looking Into Intellia Therapeutics's Recent Short Interest
Portfolio Pulse from Benzinga Insights
Intellia Therapeutics (NYSE:NTLA) has seen an 8% increase in short interest, with 18.35% of its float sold short. This is higher than its peers' average of 14.44%. The high short interest could indicate bearish sentiment, but it doesn't guarantee a price drop.
October 29, 2024 | 1:45 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Intellia Therapeutics has experienced an 8% increase in short interest, now at 18.35% of its float, which is higher than its peers' average. This could indicate bearish sentiment, but doesn't necessarily predict a price drop.
The increase in short interest suggests that investors are more bearish on Intellia Therapeutics compared to its peers. However, high short interest can also lead to a short squeeze, potentially driving the price up if traders rush to cover their positions. Therefore, the short-term impact on the stock price is uncertain.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100